The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Matched comparison of tisa-cel and axi-cel in R/R DLBCL
Emmanuel Bachy, MD, PhD, Lyon Sud Hospital Center, Lyon, France, shares the results of a real-world study comparing the safety and efficacy of tisagenlecleucel (tisa-cel) and axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The study found that patients treated with axi-cel had a prolonged progression-free survival (PFS) and overall survival (OS), but experienced higher rates of toxicity. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
